Compare Bristol-Myers Squibb Co (BMY) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Sirius XM Holdings Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.53 (market cap $116.30B), while Sirius XM Holdings Inc trades at $30.78 (market cap $10.23B). The key difference: Bristol-Myers Squibb Co is far larger — about 11.4× Sirius XM Holdings Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | SIRI | |
|---|---|---|
Market Cap | $116.30B | $10.23B |
Sector | Health | Media |
52-Week High | $62.37 | $30.75 |
52-Week Low | $42.60 | $19.92 |
Enterprise Value | $152.24B | $19.90B |
Dividend Yield | 4.42% | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Sirius XM Holdings (SIRI) trades at $30.67, up 0.82% with strong technical momentum and bullish moving average signals. The company shows improved fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after a challenging 2024. Recent developments include a strategic advertising partnership with YouTube and potential merger discussions with iHeartMedia, driving positive investor sentiment.
The outlook remains positive with analysts maintaining a $31.17 consensus target and 58% buy ratings. Key opportunities include revenue diversification through new partnerships and strong cash flow generation supporting dividends and buybacks. Risks include intense media competition and high debt levels despite recent improvement from 94% to 36% debt-to-asset ratio since 2022.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
